Cargando…

First platelet transfusion refractoriness in a patient with acute myelocytic leukemia: A case report

BACKGROUND: Platelet transfusion is of great significance in the treatment of thrombocytopenia caused by myelosuppression during intensive chemotherapy in patients with acute leukemia. In recent years, with platelet transfusion increasing, ineffective platelet transfusion has become increasingly pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Sheng-Ke, Fan, Hong-Jie, Shi, Zi-Wei, Li, Xiao-Lan, Li, Min, Song, Kui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631405/
https://www.ncbi.nlm.nih.gov/pubmed/37946754
http://dx.doi.org/10.12998/wjcc.v11.i29.7156
_version_ 1785132364833226752
author Tu, Sheng-Ke
Fan, Hong-Jie
Shi, Zi-Wei
Li, Xiao-Lan
Li, Min
Song, Kui
author_facet Tu, Sheng-Ke
Fan, Hong-Jie
Shi, Zi-Wei
Li, Xiao-Lan
Li, Min
Song, Kui
author_sort Tu, Sheng-Ke
collection PubMed
description BACKGROUND: Platelet transfusion is of great significance in the treatment of thrombocytopenia caused by myelosuppression during intensive chemotherapy in patients with acute leukemia. In recent years, with platelet transfusion increasing, ineffective platelet transfusion has become increasingly prominent. Generally speaking, platelet antibodies can be produced after repeated transfusion, thus rendering subsequent platelet transfusion ineffective. We report a case of first platelet transfusion refractoriness (PTR) in a patient with acute myelocytic leukemia (AML). Due to the rarity of such cases in clinical practice, there have been no relevant case reports so far. CASE SUMMARY: A 51-year-old female patient attended the hospital due to throat pain and abnormal blood cells for 4 d. Her diagnosis was acute myelocytic leukemia [M2 type Fms related receptor tyrosine kinase 3, Isocitrate Dehydrogenase 1, Nucleophosmin 1, Neuroblastoma RAS viral oncogene homolog (+) high-risk group]. She was treated with "IA" (IDA 10 mg day 1-3 and Ara-C 0.2 g day 1-5) chemotherapy. When her condition improved, the patient was discharged from the hospital, instructed to take medicine as prescribed by the doctor after discharge, and returned to the hospital for further chemotherapy on time. CONCLUSION: We report a rare case of first platelet transfusion failure in a patient with AML during induction chemotherapy, which may be related to the production of platelet antibodies induced by antibiotics and excessive tumor load. This also suggests that we should consider the influence of antibiotics when the rare situation of first platelet transfusion failure occurs in patients with AML. When platelet antibodies are produced, immunoglobulins can be used to block antibodies, thereby reducing platelet destruction. For patients with PTR, both immune and non-immune factors need to be considered and combined in clinical practice along with individualized treatment to effectively solve the problem.
format Online
Article
Text
id pubmed-10631405
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-106314052023-11-09 First platelet transfusion refractoriness in a patient with acute myelocytic leukemia: A case report Tu, Sheng-Ke Fan, Hong-Jie Shi, Zi-Wei Li, Xiao-Lan Li, Min Song, Kui World J Clin Cases Case Report BACKGROUND: Platelet transfusion is of great significance in the treatment of thrombocytopenia caused by myelosuppression during intensive chemotherapy in patients with acute leukemia. In recent years, with platelet transfusion increasing, ineffective platelet transfusion has become increasingly prominent. Generally speaking, platelet antibodies can be produced after repeated transfusion, thus rendering subsequent platelet transfusion ineffective. We report a case of first platelet transfusion refractoriness (PTR) in a patient with acute myelocytic leukemia (AML). Due to the rarity of such cases in clinical practice, there have been no relevant case reports so far. CASE SUMMARY: A 51-year-old female patient attended the hospital due to throat pain and abnormal blood cells for 4 d. Her diagnosis was acute myelocytic leukemia [M2 type Fms related receptor tyrosine kinase 3, Isocitrate Dehydrogenase 1, Nucleophosmin 1, Neuroblastoma RAS viral oncogene homolog (+) high-risk group]. She was treated with "IA" (IDA 10 mg day 1-3 and Ara-C 0.2 g day 1-5) chemotherapy. When her condition improved, the patient was discharged from the hospital, instructed to take medicine as prescribed by the doctor after discharge, and returned to the hospital for further chemotherapy on time. CONCLUSION: We report a rare case of first platelet transfusion failure in a patient with AML during induction chemotherapy, which may be related to the production of platelet antibodies induced by antibiotics and excessive tumor load. This also suggests that we should consider the influence of antibiotics when the rare situation of first platelet transfusion failure occurs in patients with AML. When platelet antibodies are produced, immunoglobulins can be used to block antibodies, thereby reducing platelet destruction. For patients with PTR, both immune and non-immune factors need to be considered and combined in clinical practice along with individualized treatment to effectively solve the problem. Baishideng Publishing Group Inc 2023-10-16 2023-10-16 /pmc/articles/PMC10631405/ /pubmed/37946754 http://dx.doi.org/10.12998/wjcc.v11.i29.7156 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Case Report
Tu, Sheng-Ke
Fan, Hong-Jie
Shi, Zi-Wei
Li, Xiao-Lan
Li, Min
Song, Kui
First platelet transfusion refractoriness in a patient with acute myelocytic leukemia: A case report
title First platelet transfusion refractoriness in a patient with acute myelocytic leukemia: A case report
title_full First platelet transfusion refractoriness in a patient with acute myelocytic leukemia: A case report
title_fullStr First platelet transfusion refractoriness in a patient with acute myelocytic leukemia: A case report
title_full_unstemmed First platelet transfusion refractoriness in a patient with acute myelocytic leukemia: A case report
title_short First platelet transfusion refractoriness in a patient with acute myelocytic leukemia: A case report
title_sort first platelet transfusion refractoriness in a patient with acute myelocytic leukemia: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631405/
https://www.ncbi.nlm.nih.gov/pubmed/37946754
http://dx.doi.org/10.12998/wjcc.v11.i29.7156
work_keys_str_mv AT tushengke firstplatelettransfusionrefractorinessinapatientwithacutemyelocyticleukemiaacasereport
AT fanhongjie firstplatelettransfusionrefractorinessinapatientwithacutemyelocyticleukemiaacasereport
AT shiziwei firstplatelettransfusionrefractorinessinapatientwithacutemyelocyticleukemiaacasereport
AT lixiaolan firstplatelettransfusionrefractorinessinapatientwithacutemyelocyticleukemiaacasereport
AT limin firstplatelettransfusionrefractorinessinapatientwithacutemyelocyticleukemiaacasereport
AT songkui firstplatelettransfusionrefractorinessinapatientwithacutemyelocyticleukemiaacasereport